Compare SFNC & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFNC | QURE |
|---|---|---|
| Founded | 1903 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | 2002 | 2013 |
| Metric | SFNC | QURE |
|---|---|---|
| Price | $23.36 | $23.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $26.07 | ★ $60.37 |
| AVG Volume (30 Days) | 1.8M | ★ 2.3M |
| Earning Date | 10-15-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $10.72 | $54.78 |
| Revenue Next Year | $2.97 | $356.14 |
| P/E Ratio | $25.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.00 | $8.73 |
| 52 Week High | $24.32 | $70.88 |
| Indicator | SFNC | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 61.89 | 36.59 |
| Support Level | $23.33 | $22.32 |
| Resistance Level | $24.10 | $25.61 |
| Average True Range (ATR) | 0.46 | 1.20 |
| MACD | 0.15 | 0.86 |
| Stochastic Oscillator | 87.19 | 90.45 |
Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. Its loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.